Virology & Mycology Infectious Diseases
 
   Publications A-Z
A
»
» Addiction Research & Therapy
»
»
»
»
»
»
»
»Advance Research in Meteorological Sciences
»
»Aging Science
»
»AIDS & Clinical Research
»Alcoholism and Drug Dependence
»Allergy & Therapy
»
»
»Alzheimers Disease & Parkinsonism
»Analytical & Bioanalytical Techniques
»Anaplastology
»Anatomy & Physiology
»Ancient Diseases & Preventive Remedies
»
»Anesthesia & Clinical Research
»
»Antivirals & Antiretrovirals
»Anthropology
»
»
»Aquaculture Research & Development
»
»
»
»
»Autacoids
»
  
B
»Bacteriology & Parasitology
»Bioanalysis & Biomedicine
»Biochemistry and Analytical Biochemistry
»
»Biochips & Tissue Chips
»
»
»Bioengineering & Biomedical Science
»Bioequivalence & Bioavailability
»Biosafety & Health Education
»Biofertilizers & Biopesticides
»Biometrics & Biostatistics
»
»
»
»Bioprocessing & Biotechniques
»Bioremediation & Biodegradation
»
»Biosensors & Bioelectronics
»Biotechnology & Biomaterials
»Bioterrorism & Biodefense
»Blood Disorders & Transfusion
»
»
»
»
  
C
»Cancer Science & Therapy
»Carcinogenesis & Mutagenesis
»Cardiovascular Diseases & Diagnosis
»Cardiovascular Pharmacology: Open Access
»
»Cell Science & Therapy
»Chemical Engineering & Process Technology
»
»Child and Adolescent Behavior
»Chromatography & Separation Techniques
»
»
»Clinical & Cellular Immunology
»
»Clinical & Experimental Cardiology
»Clinical & Experimental Dermatology Research
»Clinical & Experimental Ophthalmology
»Clinical & Experimental Pathology
»Clinical & Experimental Pharmacology
»
»
»Clinical Research & Bioethics
»Clinical Research on Foot & Ankle
»Clinical Toxicology
»
»
»Communicable & Noncommunicable Diseases
»Community Medicine & Health Education
»Computational Chemistry: Open Access
»Computer Science & Systems Biology
» Current Synthetic & Systems Biology
»Cytology & Histology
D
»Data Mining in Genomics & Proteomics
»
»Dentistry
»
»
»Diabetes & Metabolism
»
»Drug Metabolism & Toxicology
  
E
»Earth Science & Climatic Change
»Ecosystem & Ecography
»Endocrinology & Metabolic Syndrome
»Entomology, Ornithology & Herpetology
»Environmental & Analytical Toxicology
»Epidemiology: Open Access
»
»
»
»
»
»Experimental Sciences: Open Access
  
F
»
»
»
»Fisheries & Livestock Production
»Food Processing & Technology
»Forensic Research
»
»
  
G
»Gastrointestinal & Digestive System
»Genetic Syndromes & Gene Therapy
»
»
»Glycomics & Lipidomics
»Gynecology& Obstetrics
»General Medicine
»General Practice
»
»
»
»
»Global Economics
  
H
»
»Hematology & Thromboembolic Diseases
»
»Health & Medical Informatics
»Hereditary Genetics
»Herpetology-Open Access
»
»Horticulture
»
»Human Genetics & Embryology
»Hydrology: Current Research
»
  
I
»
»
»Infectious Diseases and Therapy
»
»
»
»
»International Journal of Physical Medicine & Rehabilitation
  
L
»
» Leukemia
  
M
»Marine Science: Research & Development
»
»
»Medicinal Chemistry
»
»
»Medical Microbiology & Diagnosis
»Medical & Surgical Urology
»Membrane Science & Technology
»
»Metabolomics:Open Access
»Microbial & Biochemical Technology
»Modern Chemistry & Applications
»
»Molecular Biomarkers & Diagnosis
»Molecular Imaging & Dynamics
»Molecular Pharmaceutics & Organic Process Research
»Mycobacterial Diseases
N
»Natural Products Chemistry & Research
»Nanomedicine & Biotherapeutic Discovery
»Nanomedicine & Nanotechnology
»
»Nephrology & Therapeutics
»Neurology & Neurophysiology
»Neurological Disorders
»
»Nuclear Medicine & Radiation Therapy
»Nutrition & Food Sciences
»Nutritional Disorders & Therapy
»
  
O
»
»Oceanography-Open Access
»Occupational Medicine & Health Affairs
»
»
»
»Organic Chemistry: Current Research
»Orthopedic & Muscular System: Current Research
»Otolaryngology
  
P
»
»
»
»Pediatrics & Therapeutics
»Petroleum & Environmental Biotechnology
»Pharmaceutica Analytica Acta
»
»Pharmacogenomics & Pharmacoproteomics
»Pharmacovigilance
»Physical Chemistry & Biophysics
»Plant Pathology & Microbiology
»Plant Biochemistry & Physiology
»Pollution Effects & Control
»political Sciences & public affairs
»Poultry, Fisheries & Wildlife Sciences
»
»
»
»
»Proteomics & Bioinformatics
»
»Psychology & Psychotherapy
»
»Pulmonary & Respiratory Medicine
  
R
»
»Reproductive System & Sexual Disorders
»Rheumatology: Current Research
»Rice research
  
S
»
»
»Social & Economical Issues of Biotechnology
»
»Sociology and Criminology-Open Access
»Sports Medicine & Doping Studies
»
»Stem Cell Research & Therapy
»Steroids & Hormonal Science
»
»Surgery: Current Research
  
T
»
»
»Thermodynamics & Catalysis
»
»Tissue Science & Engineering
»Translational Medicine
»Transplantation Technologies & Research
»Transcriptomics: Open Access
»
»Tropical Diseases
»Tropical Medicine and Surgery
»
  
V
»Vaccines & Vaccination
»
»Veterinary Science & Technology
»Virology & Mycology
»
  
W
»
  
Y
»Yoga & Physical Therapy
 
   Browse by Subjects
Clinical
» AIDS & Clinical Research
» Anesthesia & Clinical Research
» Cancer Science & Therapy
» Carcinogenesis & Mutagenesis
» Cell Science & Therapy
» Clinical & Cellular Immunology
» Clinical & Experimental Cardiology
» Clinical & Experimental Dermatology Research
» Clinical & Experimental Ophthalmology
» Clinical & Experimental Pathology
» Clinical & Experimental Pharmacology
»
» Clinical Research & Bioethics
»
» Clinical Toxicology
» Cytology & Histology
» Forensic Research
»
» Neurology & Neurophysiology
»
» Pulmonary & Respiratory Medicine
» Stem Cell Research & Therapy
» Transplantation Technologies & Research
   
Pharmaceutical Sciences
»
»
» Antivirals & Antiretrovirals
» Bioanalysis & Biomedicine
»
» Bioequivalence & Bioavailability
»
»
» Drug Metabolism & Toxicology
»
»
»
» Pharmaceutica Analytica Acta
»
» Vaccines & Vaccination
   
Chemistry
» Analytical & Bioanalytical Techniques
» Chromatography & Separation Techniques
» Medicinal Chemistry
»
»
» Organic Chemistry
»
» Physical Chemistry & Biophysics
» Thermodynamics & Catalysis
   
Environmental
»
» Aquaculture Research & Development
»
»
» Earth Science & Climatic Change
» Ecosystem & Ecography
» Environmental & Analytical Toxicology
»
»
» Hydrology: Current Research
»
» Petroleum & Environmental Biotechnology
»
»
   
Omics
»Computational Chemistry: Open Access
» Computer Science & Systems Biology
» Data Mining in Genomics & Proteomics
» Glycomics & Lipidomics
» Health & Medical Informatics
» Metabolomics:Open Access
» Pharmacogenomics & Pharmacoproteomics
» Probiotics & Health
» Proteomics & Bioinformatics
   
Life Sciences
»
»
»
»
»
»
» Bacteriology & Parasitology
»
»
» Biochemistry and Analytical Biochemistry
» Biochips & Tissue Chips
»
» Bioengineering & Biomedical Science
» Biofertilizers & Biopesticides
» Biometrics & Biostatistics
»
» Bioremediation & Biodegradation
»
» Biosensors & Bioelectronics
» Biotechnology & Biomaterials
» Bioterrorism & Biodefense
»
»
»
»
»
»
»
»
»
»
»
»
»
» Marine Science: Research & Development
»
»
» Membrane Science & Technology
» Microbial & Biochemical Technology
» Molecular Imaging & Dynamics
» Nanomedicine & Biotherapeutic Discovery
» Nanomedicine & Nanotechnology
» Nutrition & Food Sciences
»
»
» Plant Pathology & Microbiology
»
» Probiotics & Health
»
»
»
»
» Social & Economical Issues of Biotechnology
» Tissue Science & Engineering
»
»
» Veterinary Science & Technology
»
»Virology & Mycology
»
» Yoga & Physical Therapy
   
Engineering
»
»
»
»
»
»
»
» Bioprocessing & Biotechniques
» Chemical Engineering & Process Technology
»
»
» Food Processing & Technology
»
»
»
»
»
»
»
»
»
   
Medical Sciences
» Addiction Research & Therapy
»
»
» Allergy & Therapy
»
» Alzheimers Disease & Parkinsonism
» Anaplastology
» Anatomy & Physiology
»
»
»
» Autacoids
»
» Blood Disorders & Transfusion
»
»
» Cardiovascular Diseases & Diagnosis
»
»
»
» Communicable & Noncommunicable Diseases
» Community Medicine & Health Education
» Dentistry
»
» Diabetes & Metabolism
»
»
» Endocrinology & Metabolic Syndrome
» Entomology, Ornithology & Herpetology
» Epidemiology: Open Access
»
»
»
» Gastrointestinal & Digestive System
» Genetic Syndromes & Gene Therapy
»
»
»
» Gynecology& Obstetrics
»
»
» Hereditary Genetics
»
» Human Genetics & Embryology
»
»
» International Journal of Physical Medicine & Rehabilitation
»
»
»
» Medical Microbiology & Diagnosis
» Medical & Surgical Urology
»
»
» Molecular Biomarkers & Diagnosis
» Mycobacterial Diseases
»
» Nephrology & Therapeutics
»
»
» Nuclear Medicine & Radiation Therapy
»
» Nutritional Disorders & Therapy
»
»
»
»
» Orthopedic & Muscular System
» Otolaryngology
»
»
»
» Pediatrics & Therapeutics
»
» Psychology & Psychotherapy
»
» Reproductive System & Sexual Disorders
» Rheumatology: Current Research
»
»
» Sports Medicine & Doping Studies
» Steroids & Hormonal Science
» Surgery: Current Research
»
» Translational Medicine
»
»
»
 
Management
»
»
»
»
»
»
»
»
»
»
»
»
»
 
   Conferences
Upcoming Conferences
»
»
»
»
»
»
»
»
»
»
»
»
»
»
»
»
»
»
»
»
»
»
»
»
»
»
»
»
»
»
»
»
»
»
»
»
»
»
»
»
»
»
»
»
»
»
»
»
»
»
»
»
»
»
»
»
»
»
»
»
»
»
»
»
»
»
»
»
»
»
»
»
»
»
»
»
»
»
»
»
»
Previous Conferences Organized/Co-organized
»
»International Summit on GMP & GCP: USA, Europe, Japan, Asia Pacific December 03-05, 2012 DoubleTree by Hilton Philadelphia Center City, USA
»International Conference on QA, QC and Validation, December 03-05, 2012 DoubleTree by Hilton Philadelphia Center City, USA
»2nd International Conference on Nanotek and Expo, December 03-05, 2012 DoubleTree by Hilton Philadelphia Center City, USA
»International Conference and Exhibition on Obesity and Weight Management, December 03-05, 2012 at DoubleTree by Hilton Philadelphia, USA.
»International conference on Hair Transplantation and Trichology November 26-28, 2012 San Antonio, USA.
»International Conference on Anesthesia & Perioperative Care during November 26-28, 2012 San Antonio, USA.
»International Toxicology Summit & Expo November 26-28, 2012 Hilton San Antonio Airport, USA
»International Conference and Exhibition on Surgery & Transplantation November 26-28, 2012 Hilton San Antonio Airport, USA.
»International Conference and Exhibition on Food Processing and Technology November 22-24, 2012 Hyderabad, India.
»3rd International Conference and Exhibition on Analytical & Bioanalytical Techniques November 22-24, 2012 Hyderabad International Convention Center, India
»2ndInternational Conference and Exhibition on Pharmaceutical Regulatory Affairs November 23-24, 2012 HICC Hyderabad, India
»International Conference and Exhibition on Cosmetology & Cosmetics November 23-24, 2012 HICC Hyderabad, India.
»International Conference on Genetic Syndromes & GeneTherapy November 19-21, 2012 Hilton San Antonio Airport, USA
»Global Biofuels and Bioproducts Summit November 19-21, 2012 San Antonio, USA.
»International Conference and Exhibition on Probiotics-2012, November 1921, 2012, Hilton San Antonio Airport, USA.
»2nd World Congress on Cell Science and Stem Cell Research, November 12-14, 2012 Hilton San Antonio Airport, USA.
»International Conference on Regenerative and Functional Medicine, November 12-14, 2012 at San Antonio, Texas, USA.
»International Conference on Clinical Microbiology & Microbial Genomics November 12-14, 2012 San Antonio, USA.
» International Confeernce on Pulmonary & Respiratory Medicine October 29 - 31, 2012 Chicago, USA
»International Conference and Exhibition on Computer Aided Drug Design & QSAR October 29-31, 2012, Chicago, USA.
»International Conference on Clinical and Cellular Immunology October 22-24, 2012 Las Vegas, USA.
»International Conference and Expo on Material science and Engineering October 22-24, 2012 DoubleTree by Hilton Chicago-North Shore, USA.
» International Expo and Conference on Analytrix & HPLC October 22-24, 2012 Hilton Northbrook, Chicago, USA.
»International Conference on Forensic Research & Technology October 15 - 17, 2012 DoubleTree by Hilton Chicago - Northshore, USA.
»International Conference and Exhibition on Otolaryngology October 15 - 17, 2012 DoubleTree by Hilton Chicago - Northshore, USA.
»International conference on Biothreats and Biodefense October 15 - 17, 2012 DoubleTree by Hilton Chicago - Northshore, USA.
»International Conference on Tissue Science and Engineering October 1-3, 2012 DoubleTree by Hilton Chicago-North Shore, USA.
»International conference and Exhibition on Pharmacovigilance and Clinical Trials October 1-3, 2012 DoubleTree by Hilton Chicago-North Shore, USA.
»International Conference on Emerging Cell Therapies October 1-3, 2012 DoubleTree by Hilton Chicago-North Shore, USA.
»3rd World Congress on Diabetes & Metabolism which is to be held on September 24-26, 2012 Marriott Convention Center, Hyderabad, India.
»2nd International Conference on Pediatrics & Gynecology September 24-26, 2012, Hyderabad Marriott Hotel & Convention Centre , Hyderabad, India.
»International Conference on Translational medicine-2012, September 17-19, 2012 Holiday Inn San Antonio, Texas, USA.
»3rd World Congress on Biotechnology September 13-15, 2012 HICC, Hyderabad, India
»International Conference on Biodiversity & Sustainable Energy Development September 14-15, 2012 Hyderabad, India.
» International Conference on Agricultural & Horticultural Sciences September 14-15, 2012 Hyderabad International Convention Center, India
» International Conference on Hotel and Business Management September 14-15, 2012 Hyderabad International Convention Center, India
»International Conference on Hydrology and Groundwater Expo September 10-12, 2012 Hilton San Antonio Airport, USA.
»2nd World Congress on Cancer Science & Therapy September 10-12, 2012 San Antonio, USA.
»International Conference and Exhibition on Biowaivers and Biosimilars September 10-12, 2012 San Antonio, TX, USA.
»International Conference on Central Nervous System September 5-7, 2012 Double by Hilton Philadephia, USA.
»International Conference on Occupational Health and Safety Summit September 5-7, 2012 Philadelphia, USA.
»International Conference and Exhibition on pathology August 27-29, 2012 Philadelphia, USA.
»International Conference and Exhibition on Nutritional Science & Therapy-2012 August 27-29, 2012 Philadelphia, USA.
»International Conference and Exhibition on Addiction Research & Therapy August 20-22, 2012 Las Vegas, USA.
»International Conference and Exhibition on Nephrology and Therapeutics August 20-22, 2012 Chicago Chicago, USA.
»2nd International Conference on Vaccines & Vaccination August 20-22, 2012 at Chicago, USA.
»2nd World Congress on Virology August 20-22, 2012 Las Vegas, USA.
»World Congress on Earth Science & Climate Change August 21-22, 2012 Chicago, USA.
»International Conference and Exhibition on Orthopedics August 13-15, 2012 Chicago, USA.
»International Conference and Exhibition on Rheumatology & Therapeutics August 1415, 2012 at Chicago, USA
»3rd International Conference on Biomarkers & Clinical Research July 2-4, 2012 Las Vegas, USA.
»2nd International Conference on Proteomics & Bioinformatics July 2-4, 2012 Las Vegas, USA.
» International Conference and Exhibition on Neurology &Therapeutics; May 14-16, 2012 Las Vegas, USA.
»International Conference and Exhibition on Biosensors & Bioelectronics May 14-16, 2012 Las Vegas, USA.
»3rd World Congress on Bioavailability & Bioequivalence: Pharmaceutical R & D Summit March 26-28, 2012 Marriott Hotel, Hyderabad, India.
»International Conference & Exhibition on Nanotechnology and Nanomedicine March 12-14, 2012 Omaha, USA.
»World Congress on Gastroenterology and Urology March 12-14, 2012 Omaha, USA
»International Conference and Exhibition on Biometrics & Biostatistics March 5-7, 2012 Omaha, USA.
»2nd World Congress on Clinical & Experimental Dermatology March 5-7, 2012 Omaha, USA
»2nd World Congress on Clinical & Experimental Cardiology March 5-7, 2012 Omaha, USA.
» 2nd World Congress on Clinical & Experimental Ophthalmology March 5-7, 2012 Omaha, USA.
»International Conference and Exhibition on Metabolomics & Systems Biology February 20-22, 2012 San Francisco, USA.
»2nd World Congress on Pharmaceutics & Novel Drug Delivery Systems February 20-22, 2012 San Francisco, USA.
»2nd world Congress on Analytical and Bioanalytical Techniques December 16-17, 2011 San franscico, USA.
»2nd World Congress on Diabetes & Metabolism December 6-8, 2011 Philadelphia, USA.
»World Congress on Pediatrics & Gynecology December 6-8, 2011 Philadelphia, USA.
»International Conference and Exhibition on Cell Science & Stem Cell Research Nov 29-Dec 1, 2011 Philadelphia, USA.
»2nd World Congress on Biotechnology Nov 29 -Dec 1, 2011 Philadelphia, USA.
»International Conference and Exhibition on Vaccines & Vaccination November 22-24, 2011 Philadelphia, USA.
»2nd World Congress on Biomarkers & Clinical Research September 12-14, 2011 Baltimore, USA.
»International Conference and Exhibition on Virology September 5-7, 2011 Baltimore, USA.
»International Conference and Exhibition on Pharmaceutical Regulatory Affairs September 6-7, 2011 Baltimore, USA.
»International Conference and Exhibition on Cancer Science & Therapy August 15-17, 2011 Las Vegas, USA.
»International Conference on Clinical Research: Dermatology, Ophthalmology and Cardiology July 5-6, 2011 San Francisco, USA.
»International Conference & Exhibition on Proteomics & Bioinformatics June 6-8, 2011 HICC, Hyderabad, India.
»International Conference & Exhibition on Pharmaceutical Biotechnology June 6-8, 2011 HICC, Hyderabad, India.
»2nd World Congress on Bioavailability & Bioequivalence: Pharmaceutical R & D Summit June 6-8, 2011 Las Vegas, USA.
»International Conference on Pharmaceutics & Novel Drug Delivery Systems June 7-8, Las Vegas, USA.
»World Congress on Biotechnology March 21-23, 2011 Hyderabad, India.
»International Conference on Diabetes and Metabolism December 13-14, 2010 Santa Clara, USA.
»International Conference on Biomarkers & Clinical Research November 22-23, 2010 Santa Clara, USA
»International Conference and Exhibition on Analytical and Bioanalytical Techniques: Pharmaceutical R & D Summit November 01-03, 2010 Hyderabad, India
»International Conference & Exhibition on Bioequivalence & Bioavailability 2010, Pharmaceutical R & D Summit March 01-03, 2010.
»Integrating Glycomics with other Omics in Cancer Detection and Diagnosis, January 19-20, 2010, Stanford University School of Medicine.
»
»
»
»1st CCSB-2009, February 16-17, 2009
»
»

Search :     Advanced Search 

HomeHome   |   Join Join   |   Contact Contact     

  Journal of Cancer Science & Therapy     
 
Editorial Open Access
 
Direction of Gene Therapy and Virotherapy
Division of Basic and Translational Research, Department of Surgery, University of Minnesota, Minneapolis, MN 55455, USA Masato Yamamoto*
 
Corresponding Author : Masato Yamamoto, MD, PhD
Co-Director, Professor
Division of Basic and Translational Research
Department of Surgery, University of Minnesota
MoosT 11-210, 515 Delaware St SE
Minneapolis, MN 55455, USA
Tel: 612-624-9131
E-mail: [email protected]
 
Received November 20, 2012; Accepted November 23, 2012; Published November 26, 2012
 
Citation: Yamamoto M (2013) Direction of Gene Therapy and Virotherapy. J Cancer Sci Ther 5: e118. doi: 10.4172/1948-5956.1000e118
 
Copyright: 2013 Yamamoto M. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
 
Related article at
DownloadDownloadDOAJ Download
 
 
Gene therapy is a group of therapies to treat diseases by expressing gene in the body. Originally, the concept was initiated for complementation of the defective gene for hereditary diseases (e.g. ADA-SCID “the bubble boy disease, but was soon expanded to acquired diseases which include a variety of benign and malignant diseases. In this sense, the gene therapy is now a broad concept representing therapeutics which treats hereditary and acquired diseases by introducing transgene into the target cells/organs.
 
Basically, clinical functionality of gene therapy modalities are determined by the gene transfer efficiency defined by the vector system as well as the level of gene expression/transduction required to achieve the clinical effect in the target diseases. From the view point of disease specific requirement of transduction level, these numbers are largely different depending on what disease we are talking about. For hemophilia, blood coagulation factor level even at a few percent of normal control makes significant clinical impact for avoidance of bleeding from micro injuries. On the other hand, cancer treatment may require virtually 100% transduction. From the stand point of vector efficiency, most of non-viral methods tend to show low efficiency although they are less toxic in most cases. Viral vectors taking advantage of viral life cycle as “naturally engineered gene transfer machinery” are very efficient, but have drawbacks as a pathogen. Virotherapy, alternatively called oncolytic viruses, is a kind gene therapy which utilizes replication competent virus for achieving oncolysis as a result of viral replication cycle and is expected to overcome the issue of transduction efficiency by permitting cancer specific viral replication and intratumoral spread. Thus, virotherapy shares the same challenge for clinical significance with other gene therapy modalities.
 
In 1995, Dr. Harold Varmus, Director, National Institutes of Health (NIH), appointed an ad hoc committee to assess the status and promise of gene therapy and provide recommendations regarding future NIH-sponsored research in this area. So called Orkin-Motulsky Report [1] from this committee pointed out “Major difficulties at the basic level include shortcomings in all current gene transfer vectors and an inadequate understanding of the biological interaction of these vectors with the host.” So, the gene therapists at that era started variety of researches along with this line, and even now efforts to improve gene therapy modalities still are trying to answer the suggestions in this report. To this end, lots of vector improvements were made and a variety of experiments for analyzing vector-host interaction has been performed in both hereditary and acquired diseases.
 
In the gene therapy in hereditary diseases, there are several breakthrough clinical outcomes published recently. ADA-SCID gene therapy with retrovirus vector achieved expected corrections, meaning adequacy of concept, while emergence of lymph proliferative disease due to insertional geno-toxicity due to older version of the vector, which mandates further improvement of the vector [2]. (Geno-toxicity observed in this study is often stressed but achievement of clinical correction is very important point of this study as well.) AAV-2 vectorbased gene therapy for RPE65-associated Leber’s congenital amaurosis achieved good response [3]. More recently, a paper by Nathwani et al. [4] about gene therapy of hemophilia B with adenovirus-associated virus (AAV) vector was impressive. Infusion of a single dose of a serotype-8–pseudotyped, self-complementary AAV vector expressing a codon-optimized human factor IX(FIX) transgene (scAAV2/8-LP1- hFIXco) in a peripheral vein achieved expression of FIX at 2 to 11% of normal levels, and four of the six discontinued FIX prophylaxis and remained free of spontaneous hemorrhage. This positive outcome is a result of logical vector design and right choice of target disease. AAV has been used for the gene delivery for hereditary diseases but there was an issue of time line for transgene expression. The single strand DNA virus takes weeks before the virus genome is converted to double strand leading to high level transgene expression. This issue was dealt with self-complementation although this modification reduces the limit of the size of the transgene. The pseudotyping of the virus with AAV8 capsids permits favorable distribution profile without sacrificing efficient expression system derived from AAV2. More importantly, the choice of the disease was just right. The avoidance of symptomatic bleedings require only tiny fraction of restoration compared to the normal level of factor IX. However, most diseases that achieved clinical effects were so far either the ones low level complementation can make clinical significance or strong selection/survival benefits exists in genetically corrected cells. In this sense, treatment of many hereditary enzyme deficiencies is still difficult since it requires high percentage of correction and the clear survival benefit of the corrected cells. In this meaning, in vivo selection of the transduced cells reported by Paulk et al. [5] is very interesting approach and may solve the issue of low correction rate. The most important take-home message is that logical vector design and rational clinical protocol are expected to enable clinically meaningful gene expression by gene therapy.
 
In acquired diseases, most frequent target of gene therapy is cancer because its lethality makes acceptable risk of the treatment higher. On the other hand, the challenge for clinical efficacy is higher. Since the target population of cancer gene therapy/virotherapy is currently the group of patients with unresectable diseases, most patients have metastases or locally advanced lesions. The treatment of metastatic lesions requires the therapeutic effect via systemic administration or the vector function which achieves therapeutic effect in the tumors other than the originally injected region. For the locally advanced lesions, the transduction efficiency becomes the biggest issue since the residual untreated cancer cells in the tumor will lead to the quick relapse of the disease.
 
A variety of efforts has been made to enable systemic treatment of cancer. In the field of adenoviral vectors where our group is working, capsid modification is a way to change the behavior after intravenous delivery. Recent focus of adenovirus capsid modification is hexon protein. Various alternations in hyper-variable regions of adenovirus hexon protein reduce the sequestration of the virus to reticuloendothelial system (i.e. liver and spleen) via reduction of reaction with the coagulation factor X [6], which is related to the Ad induced innate immunity also [7]. In this sense, hexon modification makes a lot of sense in the context of extension of blood circulation half-life as well as reduction of toxicity.
 
On the other hand, selective transduction of target cancer cells without reducing the efficiency upon systemic delivery has been a big challenge for all gene delivery systems. Wind-type adenoviruses bind to the target cells via the binding of the fiber-knob region to the receptors on the surface of the target cells. Thus, it is logical to incorporate the selective ligand into the fiber knob region, but vast majority of the efforts fail because of rigidity of the fiber structure. After most modifications, the adenovirus cannot be assembled efficiently or loses the binding affinity even in case they are successfully assembled. Thus, identification of functional ligand is theoretically possible but is actually like “finding a needle in a haystack”. Recently, we developed a novel technology enables high efficiency Ad vector production and applied it for adenovirus targeting motif library and its high throughput screening. The screening of the Ad library (5 × 109 diversity) with target moiety expressing cells led to the identification of novel targeting motif permitting systemic targeting to the target-expressing tumor [8]. It is hoped that such advance in vector engineering enables treatment of cancers via systemic administration.
 
In the context of the therapeutic effect in uninjected lesions, immunotherapy approach is very interesting and promising. In genetic vaccine clinical trial with allogeneic GM-CSF secreting tumor immunotherapy (GVAX®), some pancreatic cancer patients showed delayed-type hypersensitivity and the target was mesothelin [9]. Another interesting approach in pancreatic cancer is interferon expressing adenovirus vector reported by Ohahsi et al. [10]. Adenovirus injection into one side of the tumor regressed the tumor on the counter side, and this effect was suppressed by NK cell depletion. This provides evidence that gene therapy with immunostimulatory molecule can provide therapeutic effect on the tumors which are not directly treated.
 
The transduction efficiency issue is a major issue because required efficiency for suppression of tumor growth is high. This is the reason that the approach producing bystander effect (e.g. HSV-TK with ganciclovir) has been preferred for gene therapy compared to the molecules whose effect is limited to the transduced cells. One interesting concept which has potential to be used for this purpose is radionuclides. A variety of radionuclides have been used for radiotherapy of cancers (e.g. 131I). If gene therapy approach can achieve selective accumulation of radionuclides to the level required for therapeutic effect, the clinical impact would be big. Dwyer et al. [11] reported such approach in prostate cancer models.
 
Another approach for transduction efficiency is to permit the injected virus to replicate in the tumor locale. The produced progeny virus infects the surrounding cells and continues to spread. If the virus is designed to replicate selectively in cancer cells, the virus will produce ultimate bystander effect by its spread and cytocidal effect specifically in cancer cells. Many viruses have been studied for this direction. Adenoviruses have been studied a lot by many groups including ours. Major benefits of Ad are well understood virology and good size for genetic manipulation. Thus, Ad is one of the best choices for detail virus engineering. The genetically modified first oncolytic adenovirus, H101, is the first virus approved by a regulatory agency in the world [12]. Many more advanced generation oncolytic adenoviruses are being developed and tested. More recently, oncolytic viruses based on herpes simplex virus (OncoVEX GM-CSF13) and vaccinia14 entered phase III clinical trial with high anticipation of clinical impact. In this sense, oncolytic virus is very attractive field for cancer gene-/viro-therapy, and a lot of vector engineering is going on for the development of next generation oncolytic viruses [13,14].
 
As described above, gene therapy researchers are improving the vectors and treatment regimen along with Orkin-Motulsky Report. However, this does not mean there isn’t much advance. The researcher in the field of gene-/viro-therapy have made significant advance both technologically and clinically. Simply, the report grasps the core feature and issue of gene therapy, and thus many issues mentioned in the report will continue to be the guideline for the improvement of gene therapy and its related technologies. Logical vector design and rational clinical protocol will lead to clinical impacts of gene therapy.
 
References
 














 


 View 

 Download    pdf version of this article

References















Select your language of interest to view the total content in your interested language
 
 
About JCST
Download
Download Editorial Board Members
Download Current Issue
Download Previous Issue
Download Archive
Download Instructions for Authors
Download Submit Manuscript
Download Contact Editorial Office
 
Article usage
  Total views: 1724
  [From(publication date):
January-2013- Feb 17, 2013]
  Breakdown by view type
  HTML page views : 945
  PDF downloads :779
 
Article Tools
Download Export citation
Download Share/Blog this article
Download Recommend to your Librarian
 
 
Special Features
Download Download PDF
Download Digital File
Download Listen Audio
Download Download Audio